Guardant Health Inc
NASDAQ:GH

Watchlist Manager
Guardant Health Inc Logo
Guardant Health Inc
NASDAQ:GH
Watchlist
Price: 35.1 USD 2.12% Market Closed
Market Cap: 4.3B USD
Have any thoughts about
Guardant Health Inc?
Write Note

Guardant Health Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Guardant Health Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Guardant Health Inc
NASDAQ:GH
Operating Income
-$522.1m
CAGR 3-Years
-9%
CAGR 5-Years
-44%
CAGR 10-Years
N/A
DaVita Inc
NYSE:DVA
Operating Income
$1.9B
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
0%
Quest Diagnostics Inc
NYSE:DGX
Operating Income
$1.3B
CAGR 3-Years
-20%
CAGR 5-Years
2%
CAGR 10-Years
3%
CVS Health Corp
NYSE:CVS
Operating Income
$11.2B
CAGR 3-Years
-8%
CAGR 5-Years
-3%
CAGR 10-Years
3%
Cigna Corp
NYSE:CI
Operating Income
$10B
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
12%
Laboratory Corporation of America Holdings
NYSE:LH
Operating Income
$1.1B
CAGR 3-Years
-34%
CAGR 5-Years
-4%
CAGR 10-Years
2%
No Stocks Found

Guardant Health Inc
Glance View

Market Cap
4.3B USD
Industry
Health Care

Guardant Health, Inc. is a precision oncology company, engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Redwood City, California and currently employs 1,373 full-time employees. The company went IPO on 2018-10-04. The firm is focused on helping conquer cancer through the use of its blood-based tests, data sets, and advanced analytics. The company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. The company also developed its Guardant Reveal liquid biopsy-based test for residual and recurring cancer to address the need for Stage II-II I colorectal cancer. Its Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes. Its Guardant360 CDx test is a liquid biopsy test measuring 55 cancer-related genes. Its GuardantOMNI test has a broader 500-gene panel, all of which analyze circulating tumor deoxyribonucleic acid (DNA) in the blood. The firm's tests are used by biopharmaceutical companies for a range of applications, including identifying patient populations to accelerate translational science research and clinical trial enrollment, and companion diagnostic.

GH Intrinsic Value
34.89 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Guardant Health Inc's Operating Income?
Operating Income
-522.1m USD

Based on the financial report for Sep 30, 2024, Guardant Health Inc's Operating Income amounts to -522.1m USD.

What is Guardant Health Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-44%

Over the last year, the Operating Income growth was 4%. The average annual Operating Income growth rates for Guardant Health Inc have been -9% over the past three years , -44% over the past five years .

Back to Top